



# 2Q21 Earnings Release

August, 2021  
Investor Relations



## 유의사항 Disclaimer

---

본 자료는 한국채택국제회계기준(K-IFRS)에 따라 작성한 휴젤 주식회사의 연결재무실적\*입니다.

본 자료에 포함된 재무실적 및 영업성과는 투자자 편의를 위하여 외부감사인의 감사가 완료되지 않은 상태에서 작성된 것으로 향후 외부감사인의 감사결과에 따라 변경될 수 있음을 양지하시기 바랍니다.

The financial information in this document are consolidated earnings\* results based on K-IFRS.

This document is provided for the convenience of investors only, before the external audit on our financial results is completed. The audit outcomes may cause some parts of this document to change.

---

# 1. 실적요약 / Financial Summary (2Q21)



[Unit: KRWbn, 십억원]

	2Q20	1Q21	2Q21	Change in %	
				YoY	QoQ
Revenue	48.3	63.8	64.5	33.7%	1.1%
COGS	15.2	16.0	17.2	13.2%	7.8%
Gross Profit	33.0	47.8	47.3	43.1%	-1.1%
(%)	68.4%	74.9%	73.3%	4.8%p	-1.7%p
SG&A	16.3	18.4	20.7	26.7%	12.7%
Operating Profit	16.7	29.5	26.6	59.1%	-9.7%
(%)	34.6%	46.2%	41.2%	6.6%p	-5.0%p
Others	5.6	-2.4	-4.4		
Pre-tax Income	22.3	27.0	22.1	-0.7%	-18.1%
Net income	15.1	19.4	15.4	1.8%	-20.8%
(%)	31.3%	30.5%	23.9%	-7.5%p	-6.6%p

## 2. 제품별 매출 / Revenue Breakdown (2Q21)



[Unit: KRWbn, 십억원]

	2Q20	(%)	1Q21	(%)	2Q21	(%)	YoY	QoQ
Toxin	26.7	55.2%	37.3	58.4%	35.3	54.7%	32.4%	-5.3%
Filler	13.5	28.0%	18.1	28.4%	21.3	33.0%	57.7%	17.6%
Cosmetics	3.1	6.4%	3.2	5.1%	2.7	4.2%	-12.5%	-17.1%
Medical device	4.6	9.5%	4.4	7.0%	4.2	6.5%	-7.9%	-5.1%
Hugel America	0.4	0.9%	0.7	1.2%	1.0	1.6%	128.0%	34.9%
<b>Total</b>	<b>48.3</b>	<b>100.0%</b>	<b>63.8</b>	<b>100.0%</b>	<b>64.5</b>	<b>100.0%</b>	<b>33.7%</b>	<b>1.1%</b>

\*J World included in Medical device segment

### 3. 지역별 매출 / Regional Breakdown (2Q21)



[Unit: KRWBn, 십억원]

		Toxin & Filler				
		2Q20	1Q21	2Q21	YoY	QoQ
Domestic		24.2	26.8	27.8	14.8%	3.8%
		16.0	28.6	28.8	80.2%	0.6%
Export	Asia	13.6	20.9	19.9	46.3%	-4.8%
	Latin America	0.4	4.0	2.8	636.2%	-29.3%
	EU/CIS	2.0	3.6	6.0	207.5%	64.9%
	Total	40.2	55.4	56.6	40.8%	2.2%

# 4. Appendix – 재무상태표 / Balance Sheet



[Unit: KRWbn, 십억원]

	2019	2020	2Q21
<b>Asset</b>			
Current Asset	640.9	668.4	662.8
Non-Current Asset	253.8	287.9	325.9
<b>Total Asset</b>	<b>894.7</b>	<b>956.3</b>	<b>988.7</b>
<b>Liability</b>			
Current Liability	37.6	43.8	40.6
Non-Current Liability	112.9	118.5	121.1
<b>Total Liability</b>	<b>150.4</b>	<b>162.3</b>	<b>161.8</b>
<b>Equity</b>			
Paid-in Capital	2.2	6.4	6.3
Capital Surplus	331.4	327.2	327.3
Other Capital Components	-397.1	-395.3	-400.5
Accumulated Other Comprehensive Income	-5.3	-0.1	1.8
Retained Earning	768.3	808.5	841.8
Non-Controlling Interests	44.8	47.4	50.3
<b>Total Equity</b>	<b>744.3</b>	<b>794.1</b>	<b>826.9</b>
<b>Total Liability and Equity</b>	<b>894.7</b>	<b>956.3</b>	<b>988.7</b>



**HUGEL**